Melanogenesis Exploitation and Melanoma Nanomedecine: Utilization of Melanogenesis Substrate, NPrCAP for Exploiting Melanoma-Targeting Drug and its Conjugation with Magnetite Nanoparticles for Developing Melanoma Chemo-Thermo-Immunotherapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-01-26

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.2174/2210289201102010005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010

  2011cited by this paper
• N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.

  2009cited by this paper
• Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy

  2009cited by this paper
• Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles.

  2009cited by this paper
• Clinical applications of magnetic nanoparticles for hyperthermia

  2008cited by this paper
• 4‐S‐Cysteaminylphenol‐loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma

  2007cited by this paper
• Hyperthermia Enhances CTL Cross-Priming1

  2006cited by this paper
• Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression

  2006cited by this paper
• Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune‐response induction in transplanted syngeneic rats

  2005cited by this paper
• Medical application of functionalized magnetic nanoparticles.

  2005cited by this paper
• Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique

  2005cited by this paper
• Immunotherapy for human cancer using heat shock protein-peptide complexes

  2005cited by this paper
• Tumor‐derived heat shock protein 70‐pulsed dendritic cells elicit tumor‐specific cytotoxic T lymphocytes (CTLs) and tumor immunity

  2004cited by this paper
• Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles

  2003cited by this paper
• Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles

  2003cited by this paper
• Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes

  2003cited by this paper
• Heat Shock Proteins : Chaperoning of Innate and Adaptive Immunities

  2003cited by this paper
• Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia

  2001cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Assembly, target-signaling and intracellular transport of tyrosinase gene family proteins in the initial stage of melanosome biogenesis.

  2000cited by this paper
• Comparison of in vitro cytotoxicity of N‐acetyl and N‐propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity

  2000cited by this paper
• Intracellular vesicular trafficking of tyrosinase gene family protein in eu- and pheomelanosome biogenesis.

  2000cited by this paper
• Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.

  1999cited by this paper
• Promotion of tyrosinase folding in COS 7 cells by calnexin.

  1999cited by this paper
• Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs.

  1999cited by this paper
• Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study.

  1999cited by this paper
• Antitumor Immunity Induction by Intracellular Hyperthermia Using Magnetite Cationic Liposomes

  1998cited by this paper
• Heat-shock protein-based anticancer immunotherapy: an idea whose time has come.

  1998cited by this paper
• Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol.

  1998cited by this paper
• Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world.

  1998cited by this paper
• Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study.

  1997cited by this paper
• Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations.

  1997cited by this paper
• Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study.

  1996cited by this paper
• Intracellular Hyperthermia for Cancer Using Magnetite Cationic Liposomes: Ex vivo Study

  1996cited by this paper
• Inhibition of Natural Killer Cell Cytotoxicity by Cell Growth‐related Molecules

  1996cited by this paper
• Selective in vivo accumulation of N-acetyl-4-S-cysteaminylphenol in B16F10 murine melanoma and enhancement of its in vitro and in vivo antimelanoma effect by combination of buthionine sulfoximine.

  1994cited by this paper
• 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity

  1994cited by this paper
• Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma.

  1993cited by this paper
• Identification of a cDNA coding for a Ca(2+)-binding phosphoprotein (p90), calnexin, on melanosomes in normal and malignant human melanocytes.

  1993cited by this paper
• 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity.

  1993cited by this paper
• Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues.

  1991cited by this paper
• Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4‐S‐cysteaminylphenol binds protein disulphide isomerase

  1991cited by this paper
• The in vivo antimelanoma effect of 4‐S‐cysteaminylphenol and its N‐acetyl derivative

  1990cited by this paper
• Effect of heat treatment on tumor cells and antitumor effector cells.

  1990cited by this paper
• Heat- or stress-inducible transformation-associated cell surface antigen on the activated H-ras oncogene-transfected rat fibroblast.

  1989cited by this paper
• Mechanism of selective toxicity of 4-S-cysteinylphenol and 4-S-cysteaminylphenol to melanocytes

  1987cited by this paper
• The heat-shock response.

  1986cited by this paper
• Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma.

  1984cited by this paper

• Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review

  2022cites this paper
• Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development

  2022cites this paper
• Elucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma

  2020cites this paper
• Synthesis of dialkylaminoaryl phosphonate bioisosteres of tyrosine and tyramine: a novel application of allene phosphonate chemistry for the synthesis of false substrates of tyrosinase -

  2015cites this paper